Three hedge funds learned of Johnson & Johnson’s acquisition of drugmaker Actelion Ltd. by tracking Johnson & Johnson’s corporate jet, Bloomberg reports. The $30 billion deal, which sent Swiss biotech Actelion shares surging, was announced Thursday, following weeks of on-again, off-again negotiations. The hedge funds — Och-Ziff Capital Management Group LLC, Eton Park Capital Management and Elliott Management Corp. — had stakes valued at $766 million, almost $500 million and $200 million respectively, Bloomberg reports. Johnson & Johnson’s corporate jet landed in Switzerland in mid-January for the first time in three months or more, Bloomberg said. Johnson & Johnson shares have declined 3.3% over the last three months, and Actelion shares have risen 88.3%, compared with a 7.7% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News